A- A A+

UK. Community pharmacy pilot provides hundreds of take-home naloxone kits in one year

Exclusive: The naloxone pilot, set up by charity Turning Point, in Somerset and Wakefield has reported providing more than 330 kits to patients in its first year. (The Pharmaceutical Journal, UK, 07.09.2021)

https://pharmaceutical-journal.com/article/news/community-pharmacy-pilot-provides-hundreds-of-take-home-naloxone-kits-in-one-year

Naloxon: Modellprojekt in Bayern erfolgreich verlaufen

München – Ein Naloxon-Modellprojekt ist nach Aussagen der Landesregierung in Bayern erfolgreich verlaufen. Das teilte heute der bayerische Gesundheitsminister Klaus Holetschek (CSU) mit. Demnach hat das Nasenspray 92 Menschen in Bayern bei Heroin- und anderen Opiatüberdosen das Leben gerettet. (arzteblatt.de, 09.09.2021)

https://www.aerzteblatt.de/nachrichten/127159/Naloxon-Modellprojekt-in-Bayern-erfolgreich-verlaufen

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another. 

Daskalakis G, Cid A, Grindrod K, Beazely MA. 

Pharmacy (Basel). 2021 Jul 23;9(3):129. doi: 10.3390/pharmacy9030129. PMID: 34449716; PMCID: PMC8396297.

https://www.mdpi.com/2226-4787/9/3/129

NALtrain/Naloxon-Training – Bundesmodellprojekt

Naloxon-Training: Dein Einsatz im Drogennotfall kann Leben retten. (2021)

https://www.naloxontraining.de/naltrain/

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another. 

Daskalakis G, Cid A, Grindrod K, Beazely MA. 

Pharmacy (Basel). 2021 Jul 23;9(3):129. doi: 10.3390/pharmacy9030129. PMID: 34449716; PMCID: PMC8396297.

https://www.mdpi.com/2226-4787/9/3/129

What is naloxone and why is it important?

Drug overdose continues to be the main cause of death among problem drug users. Heroin or other opioids — often consumed alongside other central nervous system depressants such as benzodiazepines and alcohol — are present in the majority of reported fatal overdoses (1). Overdose is common among opioid users: many of them have experienced a non-fatal overdose and most have witnessed one. Death from opioid overdose is caused primarily by respiratory depression leading to cardiac arrest.

Opioid overdose deaths can be prevented through timely administration of naloxone, a potent opioid antagonist drug that rapidly reverses the effects of opioid analgesics by binding to the opioid receptors in the central nervous system (see Spotlight: Naloxone). Because of its effectiveness, naloxone is used by emergency personnel worldwide (2). (EMCDDA, Lissabon, 31.08.2021)

https://www.emcdda.europa.eu/publications/topic-overviews/take-home-naloxone

Overdose response among trained and untrained women with a history of illicit drug use: a mixed-methods examination. 

Ataiants J, Mazzella S, Roth AM, Sell RL, Robinson LF, Lankenau SE. Overdose 

Drugs (Abingdon Engl). 2021;28(4):328-339. doi: 10.1080/09687637.2020.1818691. Epub 2020 Sep 16. PMID: 34321719; PMCID: PMC8315578.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315578/

Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. 

Desai PH, Taylor O, Shah KJ, Evoy KE, Peckham AM. 

Ment Health Clin. 2021 Jul 16;11(4):225-230. doi: 10.9740/mhc.2021.07.225. PMID: 34316417; PMCID: PMC8287869.

https://meridian.allenpress.com/mhc/article/11/4/225/468019/Characterization-of-hospitalized-patients-who

Community Case Study of Naloxone Distribution by Hospital-Based Harm Reduction Program for People Who Use Drugs in New York City. 

Riazi F, Toribio W, Irani E, Hughes TM, Huxley-Reicher Z, McBratney E, Vu T, Sigel K, Weiss JJ. 

Front Sociol. 2021 Jul 7;6:619683. doi: 10.3389/fsoc.2021.619683. PMID: 34307540; PMCID: PMC8292929.

https://www.frontiersin.org/articles/10.3389/fsoc.2021.619683/full

Associations between Naloxone Prescribing and Opioid Overdose among Patients with Acute and Chronic Pain Conditions.

Qeadan, F., and Madden, E. F. (2021) 

Addiction, doi.org/10.1111/add.15643. 

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.15643

Are opioid receptor antagonists adequate for “Opioid” overdose in a changing reality?.

Peppin, JF, Pergolizzi, JV, Dahan, A, Raffa, RB.

J Clin Pharm Ther. 2021; 46: 861– 866. doi.org/10.1111/jcpt.13320 

https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13320

Study to prevent deaths from opioid overdose shows promising results

A study undertaken in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine has shown that training people most likely to witness an opioid overdose and providing them with naloxone, a drug that reduces the effects of overdose if administered rapidly, has the potential to significantly reduce the number of deaths in these countries if scaled up nationwide. (WHO, 06.08.2021)

https://www.who.int/news/item/06-08-2021-study-to-prevent-deaths-from-opioid-overdose-shows-promising-results

USA. The US Faces a Naloxone Shortage at the Worst Possible Time

Life expectancy in the United States plunged by a year and a half in 2020, the worst year-on-year change since World War II. Drug overdoses were the second-most influential factor, behind the obvious: COVID-19. Fatal overdoses reached their highest recorded levels last year: 93,000. The surge continues into 2021 and is dovetailing with an unfathomable related crisis: a national shortage of naloxone, the “antidote” to opioid overdose. (Filter Magazine, USA, 29.07.2021)

https://filtermag.org/us-naloxone-shortage

Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia. 

Kanter K, Gallagher R, Eweje F, Lee A, Gordon D, Landy S, Gasior J, Soto-Calderon H, Cronholm PF, Cocchiaro B, Weimer J, Roth A, Lankenau S, Brenner J. 

Harm Reduct J. 2021 Jul 23;18(1):75. doi: 10.1186/s12954-021-00522-3. PMID: 34301246; PMCID: PMC8299455.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299455/

NALtrain - Konzeption, Umsetzung und Evaluation eines wissenschaftlichen Modellprojekts zur Durchführung deutschlandweiter qualitätsgesicherter Take-Home Naloxon Schulungen

Am 01.07.2021 ist das vom Bundesministerium für Gesundheit (BMG) geförderte Modellprojekt zur Nalxon-Take-Home Vergabe gestartet. Ziel ist die Befähigung von Mitarbeitenden von Drogenhilfeinrichtungen Drogengebrauchende im Umgang mit dem Naloxon-Nasenspray zu schulen. Begleitend wird ein Netzwerk an Ärzt*innen aufgebaut um die Versorgung mit Naloxon zu gewährleisten. Das Projekt wird von der deutschen Aidshilfe, Akzept e.V. und dem Institut für Suchtforschung (ISFF) durchgeführt. Wir laden Sie herzlich ein sich zu beteiligen. Weitere Informationen finden Sie auf unserer Homepage oder Sie wenden sich direkt per Mail an uns (Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!).

https://www.naloxontraining.de/

NALtrain -Konzeption, Umsetzung und Evaluation eines wissenschaftlichen Modellprojekts zur Durchführung deutschlandweiter qualitätsgesicherter Take-Home Naloxon Schulungen
Hintergrund 
Etwa 600 Menschen sind 2020 infolge des Konsums von Heroin und anderen Opioiden gestorben. Viele dieser Todesfälle hätten aber durch den Einsatz eines Naloxon-Nasensprays vermieden werden können. Das einfach und sicher anwendbare Medikament Naloxon kann innerhalb weniger Minuten die atemlähmende Wirkung von Opioiden wie Heroin, Fentanyl oder Methadon aufheben und damit Leben retten. Doch bislang kommt das Notfallmedikament viel zu wenig zum Einsatz: 2019 wurde das verschreibungspflichtige, aber erstattungsfähige Nasenspray nur etwa 370 Mal an Drogengebraucher*innen ausgegeben – bei geschätzten 165.000 Opioidkonsument*innen in Deutschland. (naloxontraining.de, Juli 2021)

https://www.naloxontraining.de/wp-content/uploads/2021/08/Infotext-NALtrain.pdf

‘Stop Overdose Safely’: How UNODC and WHO save lives by managing opioid overdose in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine

The ‘Stop Overdose Safele’ is a joint initiative from UNODC and the World Health Organization (WHO) to address opioid overdose and provide life-saving medications to those in need. The initiative serves as a platform for exchange and mutual support to effectively prevent and manage overdose. (UNODC, Wien, 06.05.2021)

https://www.unodc.org/documents/drug-treatment/UNODC_SOS_Poster_updated_November_19.pdf

Moving Beyond Narcan: A Police, Social Service, and Researcher Collaborative Response to the Opioid Crisis. 

White MD, Perrone D, Watts S, Malm A. 

Am J Crim Justice. 2021 Jul 3:1-18. doi: 10.1007/s12103-021-09625-w. Epub ahead of print. PMID: 34248322; PMCID: PMC8254616.

https://www.ncbi.nlm.nih.gov/pmc

Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose. 

Sharifi F, Meqbil YJ, Otte A, Gutridge AM, Blaine AT, van Rijn RM, Park K. 

Pharm Res. 2021 Jun 10:1–14. doi: 10.1007/s11095-021-03069-x. Epub ahead of print. PMID: 34114163; PMCID: PMC8192039.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192039/

Mit Nasenspray Leben retten

Take Home Naloxon soll Drogentod verhindern/Bundesmodellprojekt „NALtrain“ ist am 1. Juli 2021 als zentraler Baustein zur lebensrettenden Erstversorgung gestartet. (Frankfurt University of Applied Sciences, 05.07.2021)

https://idw-online.de/de/news772141

Naloxon. Bundesmodellprojekt „NALtrain“ startet am 1. Juli 2021

Take Home Naloxon (THN) durch Kurzinterventionen für Opioidkonsument*innen und Substituierte ermöglichen 

1581 Drogentodesfälle im Jahr 2020. Etwa 600 Drogentodesfälle stehen in Verbindung mit dem Konsum von Heroin und anderen Opioiden. Die Verschreibung eines Naloxon Nasensprays geschieht lediglich in Einzelfällen (2019 etwa 370 Sprays). (DAH – Deutsche AIDS-Hilfe, 24.06.2021)

https://www.naloxontraining.de/naltrain/ein-zentraler-baustein-zur-lebensrettung-bundesmodellprojekt-naltrain-startet-am-1-juli-2021/

Take-Home Naloxone: The Peoples’ Overdose Antidote

Given the high prevalence of opioid mortality rates around the globe, naloxone, an opioid antagonist, has become a crucial medication that can reverse an opioid overdose within minutes. In an attempt to bring naloxone into the community, take-home naloxone programmes provide naloxone kits together with training in overdose management and administration to members of the public. TalkingDrugs, UK, 15.06.2021)

https://www.talkingdrugs.org/ take-home-naloxone-the-peoples’-overdose-antidote

A systematic review and meta-analysis of the prevalence of take-home naloxone (THN) ownership and carriage. 

Burton G, McAuley A, Schofield J, Yeung A, Matheson C, Parkes T. 

Int J Drug Policy. 2021 May 30:103298. doi: 10.1016/j.drugpo.2021.103298. Epub ahead of print. PMID: 34078563.

https://www.sciencedirect.com/science/article/pii/S0955395921002048

Naloxon – der Lebensretter im Rucksack

Dein Einsatz im Drogennotfall kann Leben retten.  

Wir zeigen dir in drei kurzen Trainingsvideos, wie du im Drogennotfall Leben retten kannst. Außerdem kannst du ein Online-Training machen, um deinen Kenntnisstand zu überprüfen. Ein Zertifikat soll dazu beitragen, einfacher ein Rezept für Naloxon-Nasenspray bei deinem Arzt*deiner Ärztin zu erhalten. (DAH – Deutsche AIDS-Hilfe, Mai 2021)

https://www.naloxontraining.de/

Naloxone for opioid toxicity and overdose in the community. 

Jauncey M, Nielsen S. 

Aust Prescr. 2021 Apr;44(2):38-39. doi: 10.18773/austprescr.2021.006. Epub 2021 Apr 1. PMID: 33911329; PMCID: PMC8075742.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075742/

Schottland. Overdose awareness and naloxone posters go live in Scotland

This month a new overdose awareness and naloxone poster campaign launched in various cities throughout the UK.

Naloxone is a life-saving medication used to reverse the effects of opioids. It can save a person’s life if it is used quickly after an overdose is taken.

The posters feature the faces of real community naloxone carriers and their stories of why they carry naloxone, and have gone up in locations around Glasgow, Edinburgh, and Dundee, including Argyle Street in Glasgow, and Calton Road in Edinburgh. (sdf – Scottish Drugs Forum, UK, 04.05.2021)

http://www.sdf.org.uk/overdose-awareness-and-naloxone-posters-go-live-in-scotland/

USA. The Price of Saving a Life: Naloxone’s Cost Barrier in the US

When I walk into my local pharmacy to pick up a naloxone kit, I don’t need to present a prescription. I don’t even need to state my reason for needing naloxone (I’m an opioid-dependent pain patient and I frequently interview people who use illicit opioids). The pharmacist asks whether I prefer the nasal spray or the injectable version, then takes me through a five-minute orientation, explaining how to use it to save someone else’s life. Then I leave with my kit.

No money changes hands. I owe nothing. My choice of injectable versus nasal spray is driven by my own comfort, not by their respective costs. 

I live in Toronto. But in the United States, where the crisis of opioid-involved overdose deaths is raging (as it is in Canada) beyond anything we’ve seen before, naloxone access is limited—not just by stigma and outdated, restrictive laws, but also by its rising cost. (Filter, USA, 29.0.4.2021)

https://filtermag.org/naloxone-narcan-cost/

USA. FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose

FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose

The U.S. Food and Drug Administration announced today the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products. (FDA, USA, 30.04.2021)

https://www.fda.gov/news-events/press-announcements/fda-approves-higher-dosage-naloxone-nasal-spray-treat-opioid-overdose

Practical implications of naloxone knowledge among suburban people who use opioids. 

Schneider, K.E., Urquhart, G.J., Rouhani, S. et al. 

Harm Reduct J 18, 47 (2021). doi.org/10.1186/s12954-021-00466-8

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00466-8

Nobody Wants to Be Narcan'd: A Pilot Qualitative Analysis of Drug Users' Perspectives on Naloxone. 

Lai JT, Goldfine CE, Chapman BP, Taylor MM, Rosen RK, Carreiro SP, Babu KM. 

West J Emerg Med. 2021 Feb 8;22(2):339-345. doi: 10.5811/westjem.2020.10.48768. PMID: 33856321; PMCID: PMC7972385.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972385/